Eff ects of fi brates on cardiovascular outcomes: a systematic review and meta-analysis
暂无分享,去创建一个
D. Grobbee | V. Perkovic | A. Cass | J. Chalmers | B. Neal | Anushka Patel | J. Lv | S. Nicholls | Celine Foote | M. Jun | V. P. Mbbs | C. Foote
[1] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[2] Gert Mayer,et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.
[3] A. Keech,et al. Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.
[4] W. März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.
[5] P. Barter,et al. High-density lipoproteins as therapeutic targets , 2005, Current opinion in lipidology.
[6] M. Taskinen,et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] J. Kastelein,et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. , 2005, Journal of the American College of Cardiology.
[8] Richard Platt,et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.
[9] R. Karas,et al. Risk of adverse events with fibrates. , 2004, The American journal of cardiology.
[10] C. Packard. Improving outcomes through statin therapy - a review of ongoing trials , 2004 .
[11] Z. Varghese,et al. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. , 2003, Journal of the American Society of Nephrology : JASN.
[12] T. Meade,et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial , 2002, BMJ : British Medical Journal.
[13] B. Staels,et al. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[14] P. Libby,et al. PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis , 2002, Circulation research.
[15] T. Meade. Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621] , 2001, Current controlled trials in cardiovascular medicine.
[16] R. Tweedie,et al. A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis , 2000 .
[17] J. Larosa,et al. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.
[18] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[19] J Auwerx,et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.
[20] A. Nicolaides,et al. Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study , 1998, Diabetes Care.
[21] M. Nieminen,et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.
[22] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[23] Alan D. Lopez,et al. Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.
[24] J. Hokanson,et al. Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.
[25] H. Freyberger,et al. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent]. , 1994, Medizinische Klinik.
[26] Vesa Manninen,et al. Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.
[27] M. Hanefeld,et al. Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDM , 1991, Diabetes Care.
[28] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[29] W. Kannel,et al. Lipoproteins, cardiovascular disease, and death. The Framingham study. , 1981, Archives of internal medicine.
[30] E. Hutchinson,et al. Controlled trial of clofibrate in cerebral vascular disease. , 1972, Atherosclerosis.